Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win

Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win·Investor's Business Daily

Bristol Myers Squibb stock gapped higher Friday after the Big Pharma stalwart beat June-quarter forecasts and raised its outlook.

Advertisement